By Sean Moloughney, Editor01.31.23
In the years following passage of the 2018 Farm Bill, which opened a legal pathway for hemp products, dietary supplement stakeholders have been critical of FDA’s inaction on cannabidiol (CBD). So FDA’s refusal to use its current regulatory authority to grant an exception that would permit CBD dietary supplements wasn’t all that surprising; but it was disappointing to many.
“FDA continues its long exercise of kicking the can down the road while ignoring the realities of the current marketplace and offering little to show for its purported four-year review of a dietary supplement CBD regulatory pathway,” said Steve Mister, president and CEO of the Council for Responsible Nutrition (CRN), which had filed one of three citizen petitions FDA denied.
The Consumer Healthcare Products Association (CHPA) also had its petition denied. CHPA President and CEO Scott Melville said in a
“FDA continues its long exercise of kicking the can down the road while ignoring the realities of the current marketplace and offering little to show for its purported four-year review of a dietary supplement CBD regulatory pathway,” said Steve Mister, president and CEO of the Council for Responsible Nutrition (CRN), which had filed one of three citizen petitions FDA denied.
The Consumer Healthcare Products Association (CHPA) also had its petition denied. CHPA President and CEO Scott Melville said in a
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
